Manuela Zanni
A5074069337- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Telomeres, Telomerase, and Senescence
- Peptidase Inhibition and Analysis
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Ovarian cancer diagnosis and treatment
- Ubiquitin and proteasome pathways
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Hematopoietic Stem Cell Transplantation
- Cutaneous lymphoproliferative disorders research
- Pelvic and Acetabular Injuries
- Medical Imaging Techniques and Applications
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2015-2024
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
2018-2024
A. O. Ordine Mauriziano di Torino
2016
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2013-2015
University of Turin
2004-2014
Azienda Ospedaliero Universitaria San Giovanni Battista
2007-2013
Fondazione Intergruppo Italiano Linfomi Onlus
2004-2013
Institut Curie
2008-2012
Fondazione IRCCS Istituto Nazionale dei Tumori
2008
Istituto di Ematologia di Bologna
2004-2007
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Primary testicular diffuse large B-cell lymphoma (PTL) is characterized by high risk of contralateral testis and central nervous system (CNS) relapse. Chemoimmunotherapy with intrathecal (IT) CNS prophylaxis irradiation eliminates recurrences reduces relapses. The IELSG30 phase 2 study investigated feasibility activity an intensified IT IV prophylaxis. Patients stage I/II PTL who had not received treatment cycles high-dose methotrexate (MTX) (1.5 g/m2) after 6 the R-CHOP regimen (rituximab,...
Abstract The aims of this study were to define the initial pathological and clinical characteristics, prognostic factors patients with primary breast malignant lymphoma (PBL). All treated at Institut Curie for involvement reviewed. A review all cases was performed. Forty‐five selected in whom 38 diffuse large B‐cell lymphoma. complete analysis then performed on these patients. Twenty out 28 (71%) Bcl‐2 positive four (14%) had a CD10 staining. Peculiar characteristics showed nodal 58% two or...
Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in patients diffuse large B-cell lymphomas is still a matter debate. To address this point, we designed randomized phase III trial to compare rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-14 (eight cycles) sequential (R-HDS) ASCT. Patients Methods From June 2005 2011, 246 high-risk high-intermediate (56%) or high (44%) International...
Abstract The standard treatment for young patients with untreated PTCLs is based on anthracycline containing-regimens followed by high-dose-chemotherapy and stem-cell-transplantation (HDT + SCT), but only 40% of them can be cured. Romidepsin, a histone-deacetylase inhibitor, showed promising activity in relapsed PTCLs; first line, Romidepsin was added CHOP. We designed study combining romidepsin CHOEP as induction before HDT auto-SCT (PTCL-NOS, AITL/THF, ALK-ALCL), aged 18–65 years. A phase...
Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients untreated, diffuse large B-cell lymphoma, up to 40% of these relapse. Lenalidomide alone or combination rituximab has been shown be active relapsed/refractory aggressive lymphomas. In this phase I study we determined the maximum tolerated dose lenalidomide plus elderly (median age 68 years) lymphoma. Four doses (5, 10, 15, 20 mg/day on days 1–14) allocated using...
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial assessing lenalidomide (LEN) maintenance vs observation after autologous stem transplantation (ASCT) first comprehensive of different techniques, molecular markers, and tissues (peripheral blood [PB] bone marrow [BM]), taken at well-defined time points. Among 300 patients enrolled, marker was...
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cell lymphoma (MCL), R-BAC was associated complete remission rate 91% 2-year progression-free survival (PFS) 81% (95% confidence interval [CI], 68-89). Here, we report the long-term outcomes, late toxicities, results minimal residual disease (MRD) evaluation....
To investigate the impact of adding rituximab to intensive chemotherapy with peripheral-blood progenitor cell (PBPC) autograft for high-risk diffuse large B-cell lymphoma (DLB-CL) and follicular (FL).Data were collected from 10 centers associated Gruppo Italiano Terapie Innnovative nei Linfomi 522 patients DLB-CL 223 FL (median age, 47 years) who received original or a modified high-dose sequential (HDS) regimen. HDS was delivered 396 without (R-) 349 (R+) rituximab; 154 (39%) 178 (51%) in...
Abstract The complete remission (CR) rate achieved with induction chemotherapy prior to autologous stem cell transplantation (ASCT) represents the strongest prognostic factor in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). By inducing a CR of 75%, bendamustine, gemcitabine, vinorelbine (BEGEV) regimen an optimal ASCT. Presented here are 5-year results BEGEV followed by ASCT R/R cHL. With median follow-up 5 years, progression-free survival (PFS) and overall (OS) for whole...
Molecular remission (MR) is associated with improved outcome in mantle cell lymphoma (MCL). If MR not achieved, patients are at high risk of relapse. We retrospectively describe the molecular and clinical follow-ups 4 relapses (M-rels) who were treated rituximab. The received rituximab-supplemented, high-dose sequential chemotherapy autologous stem transplantation as induction treatment achieved MR. M-rel was defined polymerase chain reaction (PCR) positivity 2 consecutive samples absence...
Abstract The role of consolidation radiotherapy (RT) for bulky lesions is controversial in patients with advanced-stage Hodgkin lymphoma who achieve complete metabolic response (CMR) after doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)–based chemotherapy. We present the final results Fondazione Italiana Linfomi HD0801 trial, which investigated potential benefit RT that setting. In this phase 3 randomized study, a lesion at baseline (a mass largest diameter ≥5 cm) have CMR 2 and 6...
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it associated with cardiotoxicity, especially in older patients. Substituting doxorubicin non-PEGylated liposomal (R-COMP) may reduce risk cardiac events, but its efficacy has never been demonstrated prospective trials. We describe characteristics outcome patients DLBCL aged ≥65 years prospectively enrolled...
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on complete remission (CR) rate and benefits SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment chlorambucil plus rituximab. Study comprised an induction phase 6 mg/m2/day orally weeks 1-6, 9-10, 13-14, 17-18, 21-22, 375 mg/m2 intravenously day 1 1-4, 1400 mg 9, 13, 17, 21. Then, a followed administered at every two months for years. Of 112 enrolled,...
Fluorine 18 deoxyglucose positron emission tomography (18FDG PET) is widely used in staging of non-Hodgkin's lymphomas (NHL), but very few studies have focused on its role the initial patients with ocular adnexal lymphoma (OAL). The aim this study was therefore to evaluate 18FDG PET diagnosis ophthalmologic lymphoma. A retrospective review all imaging records, including computed (CT), magnetic resonance (MRI), and FDG PET, performed. Forty-one OAL were included study. pathologic according...
Octogenarian patients with diffuse large B-cell lymphoma are managed mainly palliation, but recent improvement in their overall condition makes potentially curative treatment a possibility. Studies have shown that half of selected octogenarians may be cured using reduced-dose anthracycline chemoimmunotherapy. However, aged >85 (late [LO]) were underrepresented, and selection criteria poorly defined. We analyzed the clinical characteristics outcomes LO enrolled FIL Elderly Project terms...